US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

RVMD Revolution Medicines Inc

44.39

0.46 (1.05%)

24 Dic 2024 - Cerrado

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

08/21/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Barbara L Weber

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Revolution Medicines (NASDAQ:RVMD)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

Haga Click aquí para más Gráficas Revolution Medicines.

Revolution Medicines (NASDAQ:RVMD)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024

Haga Click aquí para más Gráficas Revolution Medicines.

Noticias sobre Revolution Medicines Inc RVMD

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Jueves 5 de Diciembre 2024 (3 semanas hace) • GlobeNewswire Inc.

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Martes 3 de Diciembre 2024 (3 semanas hace) • GlobeNewswire Inc.

Revolution Medicines Announces Commencement of Public Offering of Common Stock
Lunes 2 de Diciembre 2024 (3 semanas hace) • GlobeNewswire Inc.

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
Lunes 2 de Diciembre 2024 (3 semanas hace) • GlobeNewswire Inc.

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
Miércoles 27 de Noviembre 2024 (4 semanas hace) • GlobeNewswire Inc.

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
Miércoles 6 de Noviembre 2024 (2 meses hace) • GlobeNewswire Inc.

Revolution Medicines to Participate in Upcoming Investor Conferences
Martes 5 de Noviembre 2024 (2 meses hace) • GlobeNewswire Inc.

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
Miércoles 30 de Octubre 2024 (2 meses hace) • GlobeNewswire Inc.

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Viernes 25 de Octubre 2024 (2 meses hace) • GlobeNewswire Inc.

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Miércoles 23 de Octubre 2024 (2 meses hace) • GlobeNewswire Inc.

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Lunes 21 de Octubre 2024 (2 meses hace) • GlobeNewswire Inc.

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
Lunes 7 de Octubre 2024 (3 meses hace) • GlobeNewswire Inc.

Más de Revolution Medicines Inc Artículos de Noticias

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones